Claudin 18.2 Targeted Therapy Market Forecast & Clinical
Claudin18.2 targeted therapy market sees Vyloy (zolbetuximab) approval in 2024, with over 60 drugs in clinical trials, focusing on gastric cancer and expanding to other tumors. China emerges as a key innovator, with Innovent, MabWorks, and Biotheus leading progress.
© Copyright 2024. All Rights Reserved by MedPath